David Baker, Vallon CEO
Microcap biotech seeks a merger or new investment after PhIII flop — shares soar
Roughly a month after its lead ADHD drug went up in flames, a microcap biotech is facing the music.
Tiny Vallon Pharmaceuticals put out a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
